In the SHARP trial, the efficacy of sorafenib, and inhibitor of vascular endothelial growth factor (VEGF) and of platelet-derived growth factor (PDGF) was assessed in 602 patients affected by Hepatocellular Carcinoma (HCC) randomly assigned to assume sorafenib or placebo. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.